---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Cost assumptions"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Cost assumptions. Topics: Vonaprument dose and frequency in ARCHER II; Medicare Part B payment limits for comparator complement inhibitors, October to December 2026; Medicare Part B spending and beneficiaries for comparator complement inhibitors, 2023 and 2024; Medicare Part B quarterly spending and beneficiaries for comparator complement inhibitors, 2025 and first quarter of 2026; 3 further topics. 7 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics/cost-assumptions"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Cost assumptions

<a id="heading-4.2.4"></a>

## 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

### Price of vonaprument

No evidence found.

<a id="topic-4.2.4-2"></a>

### Vonaprument dose and frequency in ARCHER II

> “Vonaprument (ANX007) Monthly”
> “5.0 mg/eye”

Source: [Annexon Biosciences investor event presentation (2026)](https://ir.annexonbio.com/static-files/e55e4d2a-22d8-43a8-bf8c-6449df3a261b)

<a id="topic-4.2.4-3"></a>

### Medicare Part B payment limits for comparator complement inhibitors, October to December 2026

| HCPCS code and product | Short description | Billing unit | Payment limit per billing unit (dollars) | Notes |
| --- | --- | --- | --- | --- |
| J2781 pegcetacoplan (Syfovre) | “Inj, pegcetacoplan, 1mg” | “1 MG” | “135.267” | “AMP-based payment limit” |
| J2782 avacincaptad pegol (Izervay) | “Inj avacincaptad pegol 0.1mg” | “0.1 MG” | “100.563” | Not reported |

Source: [CMS Medicare Part B Payment Limit File (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-4.2.4-4"></a>

### Medicare Part B spending and beneficiaries for comparator complement inhibitors, 2023 and 2024

| HCPCS code and product | Total spending, 2023 (dollars) | Total beneficiaries, 2023 | Total spending, 2024 (dollars) | Total claims, 2024 | Total beneficiaries, 2024 | Average spending per claim, 2024 (dollars) | Average spending per beneficiary, 2024 (dollars) |
| --- | --- | --- | --- | --- | --- | --- | --- |
| J2781 pegcetacoplan (Syfovre) | “76651580.03” | “17414” | “403855394.8” | “148576” | “29338” | “2718.173829” | “13765.60757” |
| J2782 avacincaptad pegol (Izervay) | Not reported | Not reported | “190365232.8” | “73172” | “18308” | “2601.613086” | “10397.92619” |

Source: [CMS Medicare Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/76a714ad-3a2c-43ac-b76d-9dadf8f7d890/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="topic-4.2.4-5"></a>

### Medicare Part B quarterly spending and beneficiaries for comparator complement inhibitors, 2025 and first quarter of 2026

| HCPCS code and product | Period | Total spending (dollars) | Total claims | Total beneficiaries | Average spending per claim (dollars) | Average spending per beneficiary (dollars) |
| --- | --- | --- | --- | --- | --- | --- |
| J2781 pegcetacoplan (Syfovre) | “2025 (Q1-Q4)” | “451069360.05” | “168366” | “32021” | “2679.1000561” | “14086.673122” |
| J2781 pegcetacoplan (Syfovre) | “2026 (Q1)” | “109568082.68” | “41654” | “24179” | “2630.4336361” | “4531.5390496” |
| J2782 avacincaptad pegol (Izervay) | “2025 (Q1-Q4)” | “364934587.1” | “140741” | “27497” | “2592.9515003” | “13271.796454” |
| J2782 avacincaptad pegol (Izervay) | “2026 (Q1)” | “105232261.84” | “41264” | “23315” | “2550.2196064” | “4513.5004006” |

Source: [CMS Medicare Quarterly Part B Spending by Drug (2026)](https://data.cms.gov/data-api/v1/dataset/bf6a5b3b-31ee-4abb-b1ad-2607a1e7510a/data?filter%5Bc%5D%5Bcondition%5D%5Bpath%5D=HCPCS_Cd&filter%5Bc%5D%5Bcondition%5D%5Boperator%5D=IN&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2781&filter%5Bc%5D%5Bcondition%5D%5Bvalue%5D%5B%5D=J2782)

<a id="topic-4.2.4-6"></a>

### Launch wholesale acquisition costs of comparator complement inhibitors, 2023

> “Astellas set the drug’s list price at $2,100 per vial, the spokesperson said. That’s slightly less than the $2,190-per-vial cost Apellis set for Syfovre at launch.”

Source: [Fidler (2023)](https://www.biopharmadive.com/news/astellas-iveric-fda-approval-geographic-atrophy-izervay/690052/)

<a id="topic-4.2.4-7"></a>

### Medicare payment for intravitreal injection (CPT 67028), 2025 and 2026

| CPT code | 2025 non-facility total RVUs | 2026 non-facility total RVUs | 2025 non-facility pay (dollars) | 2026 non-facility pay (dollars) | Change in non-facility pay, 2025 to 2026 |
| --- | --- | --- | --- | --- | --- |
| “67028” | “3.37” | “3.42” | “$109.01” | “$114.23” | “4.79%” |

Source: [American Academy of Ophthalmology Medicare payment comparison (2026)](https://assets.aao.org/2026-07/Office%20-%202025%20vs%202026%20Medicare%20Pay%20Final%20Rule.pdf)

<a id="topic-4.2.4-8"></a>

### Comparator dosing frequency assumed in PBAC financial estimates

> “4.71 injections per year, calculated from the totals at 24 months for the OAK and DERBY trials and adjusted for compliance (95.5%) to derive 4.5 injections per year.”
> “The PBAC advised that the number of pegcetacoplan scripts per year should be revised to reflect treatment compliance reported in the key trials (i.e. 5.39 scripts per year).”

Source: [Pharmaceutical Benefits Advisory Committee pegcetacoplan (2025)](https://www.pbs.gov.au/industry/pbac/psd/2025/11/pegcetacoplan-psd-november-2025.pdf?variant=3)

> “As such, the submission estimated that patients would require 12 scripts per year for initial treatment and 6 scripts per year for continuing treatment.”
> “A mean treatment duration of 24.99 months (derived from the modelled TTD) was applied to all eligible patients that elect treatment.”
> “Costs for the intravitreal administration of ACP was included per script using MBS item 43030 ($350.85). This was reasonable.”

Source: [Pharmaceutical Benefits Advisory Committee avacincaptad pegol (2026)](https://www.pbs.gov.au/industry/pbac/psd/2026/03/avacincaptad-pegol-psd-march-2026-a1151.pdf?variant=3)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
